When this choice actually comes up

The question tends to arise at a specific moment: a patient has an MRI report confirming a focal cartilage lesion — typically an ICRS grade III or IV defect — and a consultant has explained that two realistic restoration pathways exist. One is a single outpatient ultrasound-guided injection of a collagen scaffold (ChondroFiller injection). The other is a two-stage surgical programme in which the patient's own chondrocytes are harvested, cultured, and implanted onto a collagen membrane (MACI). Neither is a joint replacement, and neither is simply a pain-management injection; both sit within the cartilage restoration pathway.

The same clinical boundaries apply to both. Advanced or generalised osteoarthritis, bone-on-bone degeneration, unstable joint mechanics, and uncorrected malalignment are shared contraindications — patients sometimes arrive expecting one of these procedures when neither is appropriate. Both also require healthy cartilage borders surrounding the defect and a joint that is mechanically sound.

Where they separate is in invasiveness, recovery demand, defect-size match, and the depth of the evidence base — not in a simple hierarchy of one being better than the other.

How ChondroFiller injection works

During a ChondroFiller injection appointment, there is no operating theatre, no general anaesthetic, and no overnight stay. The collagen scaffold is delivered as a liquid under ultrasound guidance, with the needle placed precisely into the cartilage defect in a standard outpatient clinic setting. The whole procedure takes a matter of minutes.

Once the liquid enters the defect, it polymerises — sets into a stable hydrogel — within approximately 3–5 minutes, conforming to the contour of the lesion. That hydrogel is the working part of the treatment: an acellular (cell-free) matrix of murine-derived Type I collagen that acts as a physical scaffold. It does not bring repair cells with it. Instead, it draws them in — progenitor cells migrating from the surrounding synovium and subchondral bone move into the scaffold and, under the right conditions, begin differentiating towards cartilage. This process is termed matrix-induced chondrogenesis.

Until recently, that cell-migration mechanism rested largely on preclinical inference. A 2025 ex vivo osteochondral model provided direct cellular confirmation: ChondroFiller-treated defects showed a 2.4-fold increase in DNA content by day 14 compared with untreated controls, demonstrating that host cells were actively recruited into the scaffold rather than simply depositing on its surface.

The current evidence base covers defects up to approximately 3 cm², extendable to 6 cm² using multiple injections, and the technique has been applied across the knee, hip, ankle, shoulder, wrist, and small hand joints.

One practical implication follows directly from the scaffold's early mechanical state. A 2024 biomechanical study found that ChondroFiller gel in the initial post-injection period does not reduce damage to the opposing articular surface under cyclic loading — the hydrogel is not yet mechanically stable enough to absorb or distribute those forces. Protected weight-bearing in the weeks following injection is therefore a mechanical necessity, supported by published evidence, not an arbitrary restriction.

How MACI surgery works

MACI unfolds across two separate hospital visits, with a laboratory interval of four to six weeks in between — and that gap is central to what the procedure involves.

At the first operation, a small cartilage biopsy is taken from a low-load area of the knee joint under a keyhole arthroscopic approach. The harvested tissue is sent to a specialist laboratory, where chondrocytes are isolated, expanded in culture, and then seeded onto a Type I/III collagen membrane.

The second, more substantial operation involves surgically debriding the defect — clearing damaged tissue down to the subchondral bone to create a stable, clean base. The cell-seeded membrane is then fixed into that prepared void, and reconstruction proceeds from the bone surface upward. This is the opposite of ChondroFiller injection's additive logic: rather than placing an acellular scaffold and drawing the joint's own progenitor cells in from the margins, MACI first clears the defect and fills it with chondrocytes expanded outside the body.

NICE-approved under technology appraisal TA477, MACI is NHS-eligible for focal knee defects typically between 2 and 10 cm², offering a well-evidenced pathway for patients who meet the eligibility criteria. It is not suited to joints with significant subchondral bone loss that would require separate reconstruction, uncorrected malalignment, or patients who cannot commit to two separate surgical episodes and the interval between them.

Rehabilitation is prolonged: published protocols typically extend over 12–18 months before return to high-demand activity, reflecting the time the implanted cells require to mature into mechanically competent repair tissue.

What the clinical evidence shows for each

The published evidence for each procedure needs to be read on its own terms, because no trial has placed them in direct competition.

ChondroFiller injection outcomes

Across knee cohorts, IKDC scores improve by approximately 30 points over 12 months — a clinically meaningful gain confirmed in a dedicated knee study of 17 patients (mean age 31), where Lysholm and IKDC scores rose significantly at 3, 6, and 12 months and then plateaued, suggesting the main benefit is established within the first year. MRI fill quality, measured by MOCART scoring, has been reported in the range of 70–87, indicating reasonable scaffold integration. In the hip, a cohort of 26 patients followed for 12–60 months showed 17 of 21 evaluable patients (81%) achieving good or excellent results at 3–5 years.

The one randomised controlled trial (n=23) comparing ChondroFiller injection with microfracture found significant IKDC gains at 3, 6, and 12 months, with good MRI filling and no adverse events in the ChondroFiller group. However, 6 of the 10 patients allocated to microfracture declined their surgery — a 60% dropout rate that made any cross-group comparison statistically impossible. The trial supports ChondroFiller injection's single-arm profile but cannot function as a comparative benchmark.

MACI outcomes

MACI carries a reported success rate of approximately 75–90% in carefully selected patients, with trials demonstrating superiority over microfracture at both short- and long-term follow-up. A 2025 retrospective matched-pair analysis (n=48) found MACI equivalent to AMIC and minced cartilage implantation on every KOOS and VAS measure at the 2-year mark — a finding that modestly narrows the assumed advantage of cell-based reconstruction over single-stage alternatives at that time point, though longer-term durability data continue to favour MACI.

The evidence gap

No head-to-head randomised trial has compared ChondroFiller injection directly against MACI. That gap is material: the cost and procedural burden differ substantially — approximately £3,000–9,800 for a single outpatient appointment versus £30,000–40,000 or more for two-stage surgery — yet without comparative trial data, neither equivalence nor superiority can be claimed.

Which patients suit each pathway

Defect size provides the clearest starting point. ChondroFiller injection is most appropriate for well-contained focal lesions up to approximately 3 cm², though the CER supports extension to 6 cm² in suitable cases. MACI's NICE indication (TA477) covers the 2–10 cm² range. The practical consequence is that lesions sitting in the 2–3 cm² window do not fall neatly to either side: that overlap zone is where clinical judgement — informed by the factors below — does the real work, not a size threshold alone.

Subchondral bone status matters considerably. Where the bone plate beneath the cartilage remains intact, ChondroFiller injection addresses the cartilage void without disturbing the underlying structure. Where the subchondral plate is damaged or lost, MACI's ablative-reconstructive approach — which starts by preparing the base and rebuilds upward from it — carries a structural advantage that an injectable scaffold cannot replicate.

Joint alignment must be addressed before committing to either pathway. Both procedures are likely to fail prematurely if the repaired compartment remains mechanically overloaded; osteotomy may need to form part of the plan from the outset.

Age and BMI are genuine selection variables rather than background information. MACI's evidence base is strongest in patients under 40–45 with isolated lesions; in older patients, the cellular yield and biological environment may be less favourable. Elevated BMI raises load across the repaired surface — a concern for both pathways, but particularly relevant to ChondroFiller injection's requirement for strictly protected weight-bearing in the early weeks while the scaffold stabilises.

Finally, a history of prior microfracture is a finding that changes the conversation. Marrow-stimulation procedures breach and can permanently alter the subchondral bone plate, reducing the biological scaffold that both pathways depend on. Patients who have already had microfracture often do not realise this affects their options; it is one of the more important pieces of history to establish at consultation.

Getting an accurate assessment in London

Choosing between these two pathways is not a preference question — it is a defect-characteristics question. The characteristics that matter most (subchondral bone status, lesion geometry, joint mechanics, prior treatment history) are not reliably established without a dedicated MRI review interpreted alongside clinical examination. The comparison this article sets out clarifies what drives the decision; an accurate answer for an individual patient requires imaging and a structured clinical conversation — neither pathway can be confidently recommended, or ruled out, without both.

At London Cartilage Clinic on Harley Street, specialist assessments for focal cartilage defects cover MRI review, joint alignment evaluation, and a discussion of the full restoration pathway — from ultrasound-guided injectable scaffold options through to surgical reconstruction. Professor Paul Y. F. Lee, who leads the clinic's cartilage assessment and treatment programme, has clinical experience across both non-surgical and surgical cartilage restoration techniques.

Patients can arrange an assessment at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759